OncoMatch/Clinical Trials/NCT05701241
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Is NCT05701241 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Somatostatin analog for gastroenteropancreatic neuroendocrine tumor.
Treatment: Somatostatin analog — The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with somatostatine analogues (SSA). Eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT) or targeted therapy, at the discretion of the local investigator). Patients within each substudy will be randomised 1:1 between continuation or withdrawal from SSA at the start of second-line systemic therapy. Stratification will occur according to study site and according to the Ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade 2)).
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Grade: 12 (who 2019)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: somatostatin analogue — first-line
Documented radiological disease progression on first-line SSA treatment at label dose or higher
Cannot have received: everolimus (everolimus)
Prior treatment with everolimus
Cannot have received: sunitinib (sunitinib)
Prior treatment with sunitinib
Cannot have received: PRRT (Lutetium (177Lu) oxodotreotide)
Prior treatment with PRRT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify